Simcere Zaiming, Inc. - 10 Aug 2026 Form 4 Insider Report for NextCure, Inc. (NXTC)

Reporting relationship: Former 10% Owner
Issuer ticker: NXTC
Reported as of: 10 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Aug 2026, 11:35:04 UTC
Prior SEC filing: 29 Sep 2025
Source filing: View source filing
Reporting owner signature: Simcere Zaiming, Inc., By: /s/ Renhong Tang, Chief Executive Officer

Key filing fact

Simcere Zaiming, Inc. filed Form 4 for NextCure, Inc. (NXTC) on 12 Aug 2026.

Key facts

This page summarizes Simcere Zaiming, Inc.'s Form 4 filing for NextCure, Inc. (NXTC).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 12 Aug 2026, 11:35.

Change

Previous filing in this sequence was filed on 29 Sep 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (6)

CIK 0002080252 Primary reporting owner

Simcere Zaiming, Inc.

Relationship: Former 10% Owner
Address: 20 ACORN PARK DR., CAMBRIDGE
Signature: Simcere Zaiming, Inc., By: /s/ Renhong Tang, Chief Executive Officer
Signature date: 12 Aug 2026

CIK 0002082506

Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd.

Relationship: Former 10% Owner
Address: BUILDING 23, NO. 699-18, XUANWU AVENUE, NANJING CITY, JIANGSU PROVINCE, CHINA
Signature: Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., By: /s/ Renhong Tang, Director and Attorney-in-Fact
Signature date: 12 Aug 2026

CIK 0002088064

Simcere Zaiming Pharmaceutical Co., Ltd.

Relationship: Former 10% Owner
Address: NO. 20, YAOGUYIHENG ROAD, XIUYING DISTRICT, HAIKOU CITY, HAINAN PROVINCE, CHINA
Signature: Simcere Zaiming Pharmaceutical Co., Ltd., By: /s/ Renhong Tang, Chief Executive Officer and Chairman of the Board of Directors
Signature date: 12 Aug 2026

CIK 0002082516

Simcere Pharmaceutical Group Ltd

Relationship: Former 10% Owner
Address: BUILDING 23, NO. 699-18, XUANWU AVENUE, NANJING CITY, JIANGSU PROVINCE, CHINA
Signature: Simcere Pharmaceutical Group Limited, By: /s/ Jinsheng Ren, Chairman and Executive Director
Signature date: 12 Aug 2026

CIK 0001455397

Ren Jinsheng

Relationship: Former 10% Owner
Address: BUILDING 23, NO. 699-18, XUANWU AVENUE, NANJING CITY, JIANGSU PROVINCE, CHINA
Signature: Ren Jinsheng, /s/ Jinsheng Ren
Signature date: 12 Aug 2026

CIK 0002088593

Tang Renhong

Relationship: Former 10% Owner
Address: BUILDING 23, NO. 699-18, XUANWU AVENUE, NANJING CITY, JIANGSU PROVINCE, CHINA
Signature: Tang Renhong, /s/ Renhong Tang
Signature date: 12 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NXTC transaction

Common Stock

Sale

Transaction value
Shares: -30,000
Change %: -8.9%
Price: $6.16^*
Shares after: 308,636
Date: 10 Aug 2026
Ownership: See Footnotes
Footnotes: F1, F2, F3

NXTC transaction

Common Stock

Sale

Transaction value
Shares: -30,000
Change %: -8.9%
Price: $6.16^*
Shares after: 308,636
Date: 10 Aug 2026
Ownership: See Footnotes
Footnotes: F1, F2, F3

NXTC transaction

Common Stock

Sale

Transaction value
Shares: -30,000
Change %: -8.9%
Price: $6.16^*
Shares after: 308,636
Date: 10 Aug 2026
Ownership: See Footnotes
Footnotes: F1, F2, F3

NXTC transaction

Common Stock

Sale

Transaction value
Shares: -30,000
Change %: -8.9%
Price: $6.16^*
Shares after: 308,636
Date: 10 Aug 2026
Ownership: See Footnotes
Footnotes: F1, F2, F3

NXTC transaction

Common Stock

Sale

Transaction value
Shares: -30,000
Change %: -8.9%
Price: $6.16^*
Shares after: 308,636
Date: 10 Aug 2026
Ownership: See Footnotes
Footnotes: F1, F2, F3

NXTC transaction

Common Stock

Sale

Transaction value
Shares: -30,000
Change %: -8.9%
Price: $6.16^*
Shares after: 308,636
Date: 10 Aug 2026
Ownership: See Footnotes
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Simcere Zaiming, Inc. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

The securities reported herein were directly held by Simcere Zaiming, Inc. ("Simcere Zaiming") and may be deemed to have been indirectly beneficially owned by the other Reporting Persons.

Footnote F2

Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. ("Jiangsu Zaiming") is the sole shareholder of Simcere Zaiming. Simcere Zaiming Pharmaceutical Co., Ltd. (formerly known as Hainan Simcere Zaiming Pharmaceutical Co., Ltd.) is the sole shareholder of Jiangsu Zaiming. Simcere Pharmaceutical Group Limited ("Simcere Group") is the controlling shareholder of Simcere Zaiming Pharmaceutical Co., Ltd. through several intermediate companies. Mr. Jinsheng Ren is the chairman of the board of directors of Simcere Group and a director of Simcere Zaiming Pharmaceutical Co., Ltd. Mr. Renhong Tang is a director of Simcere Group, the chief executive officer and chairman of the board of directors of Simcere Zaiming Pharmaceutical Co., Ltd., a director of Jiangsu Zaiming and the chief executive officer and sole director of Simcere Zaiming. Messrs. Ren and Tang may be deemed to be the beneficial owners having shared voting power and shared investment power over the securities described herein.

Footnote F3

Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that any Reporting Person is the beneficial owner of any of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.

SEC remarks

This Form 4 constitutes an exit filing for the Reporting Persons, as they have ceased to be beneficial owners of more than 10% of the Issuer's common stock and therefore are no longer subject to Section 16 of the Exchange Act as a result of the sale described above.